Remove DNA Remove Engineering Remove Virus
article thumbnail

Engineering viruses to kill deadly pathogens

Science Daily: Pharmacology News

In the new study, researchers successfully modified DNA from four types of phages to kill a deadly pathogen. Antimicrobial resistance is an urgent and growing global crisis. Researchers are exploring phages, viruses that infect bacteria, as a possible solution.

Virus 104
article thumbnail

The role of CRISPR in microbiome engineering breakthroughs

Drug Target Review

When faced with a viral threat, bacterial cells developed an immune response by capturing and copying DNA fragments of viruses. This allowed bacteria to recognise subsequent attacks and cleave the viral DNA to stop the viral infection. It was also discovered that the Cas enzyme was responsible for DNA cleavage.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Eterna acquires Exacis’ allogeneic immuno-oncology platform

Drug Discovery World

Eterna Therapeutics, a life science company focused on mRNA cell engineering, has acquired Exacis Biotherapeutics’ immuno-oncology platform. In contrast to DNA-based reprogramming and gene editing, the mRNA-based approach does not expose cells to expensive and potentially harmful viruses or DNA vectors.

article thumbnail

The Importance of Hazard Communications in Clinical Trials Involving Genetic Engineering

Advarra

Recombinant DNA technologies and genetically modified biological agents are being adapted for a wide scope of therapeutic applications, and their use is becoming increasingly common in clinical trials. How can I protect myself from exposure? What should I do if I’m exposed?

article thumbnail

Drug discovery deals highlight key growth areas

Drug Discovery World

GenomeFrontier partners with BioCina on CAR-T therapy CDMO BioCina and GenomeFrontier Therapeutics will partner on the development of virus-free CAR-T products for cancer treatment. BioCina will provide process development and GMP manufacturing for Minicircle DNA and Plasmid DNA.

DNA 130
article thumbnail

Risk Assessment for use of Engineered Genetic Materials in Clinical Research

Advarra

The use of engineered genetic materials in clinical trials is rapidly expanding, with potential applications for genetic vaccines, gene-modified cellular therapies, and gene therapies. A key part of the IBC’s evaluation is assessing the risks posed by the engineered genetic materials. Why Does the IBC Need to do a Risk Assessment?

article thumbnail

Day Zero Antivirals for Future Pandemics

Codon

When COVID-19 emerged in 2019, by contrast, mRNA vaccines developed by Pfizer and Moderna took just 326 days from the initial sequencing of the virus to gaining approval for emergency use. These drugs would be ideal tools to bridge the wait for a vaccine against a quickly-spreading virus.

RNA 93